Pfizer and eFFECTOR Ink $507 Million Cancer Deal

Pfizer and eFFECTOR Ink $507 Million Cancer Deal

Source: 
BioSpace
snippet: 

Pfizer and Effector Therapeutics inked a global license and collaboration deal to develop small-molecule inhibitors of eukaryotic initiation factor 4E, also known as eIF4E.